Velocity One, a newly formed aerospace manufacturing holding company, announced the acquisition of Emcore Corp. for $31.4 ...

Alkermes plc announced today that management will participate at two upcoming investor conferences. Stifel Healthcare ConferenceDate/Time: Monday, Nov. 18, 2024 at 8:35 a.m. ET (1:35 p.m. GMT) ...

Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on PepGen Inc. (PEPG – Research Report) on November 8 and set a price target ...

The company’s shares opened today at $18.61 ... Matteis covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Vigil Neuroscience Inc, and Alkermes. Contineum Therapeutics, ...

Stifel Nicolaus upgraded shares of Alkermes (NASDAQ:ALKS – Free Report) from a hold rating to a buy rating in a research note released on Tuesday, Marketbeat Ratings reports. The firm currently has ...

Stifel has upgraded Alkermes (ALKS) to buy from hold, citing increased confidence in the company’s narcolepsy drug candidate ALKS2680. Read more here.

The consensus rating for Ultragenyx Pharmaceutical is Outperform, based on 6 analyst ratings. With an average one-year price target of $102.33, there's a potential 100.69% upside.

Myrobalan Therapeutics, a biotechnology company developing novel oral small-molecule therapies to repair damage and restore brain function in high-unm ...

About Alkermes Plc, Amicus Therapeutics and Inc. Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients ...

Alkermes (NASDAQ:ALKS – Free Report) had its price target lowered by Cantor Fitzgerald from $48.00 to $43.00 in a research ...

Adding to Goldman Sachs' analysis, InvestingPro data provides further context on Alkermes' financial position. The company's market capitalization stands at $4.34 billion, with a P/E ratio of 12. ...